Interaction between posaconazole and caspofungin in concomitant treatment of mice with systemic Aspergillus infection

Area of Science:

• Medical Mycology
• Pharmacology
• Infectious Diseases

Background:

• Systemic fungal infections caused by Aspergillus species pose a significant threat, particularly in immunocompromised individuals.
• Developing effective combination therapies is crucial for improving treatment outcomes and overcoming resistance.
• Posaconazole and caspofungin are established antifungal agents with distinct mechanisms of action.

Purpose of the Study:

• To evaluate the in vivo interaction between posaconazole and caspofungin.
• To determine if concomitant administration leads to antagonism in treating systemic Aspergillus infections.
• To assess the impact of this combination on survival rates in a murine model.

Main Methods:

• Murine model of systemic infection using Aspergillus fumigatus and Aspergillus flavus.
• Treatment groups included monotherapy with posaconazole, monotherapy with caspofungin, and combination therapy.
• Statistical comparison of survival curves between treatment groups.

Main Results:

• No antagonistic interaction was observed between posaconazole and caspofungin in the treatment of systemic Aspergillus infections.
• Survival rates in mice receiving combination therapy were comparable to or better than monotherapy groups.
• The combination did not exacerbate the infection or reduce survival compared to individual drugs.

Conclusions:

• Concomitant administration of posaconazole and caspofungin is not antagonistic in this preclinical model.
• This combination therapy warrants further investigation for the treatment of invasive aspergillosis.
• The findings support the potential utility of combining these antifungal agents.